[ad_1]
US President Donald Trump makes an announcement within the Oval Workplace of the White Home in Washington, DC on Nov. 6, 2025.
Andrew Caballero-Reynolds | AFP | Getty Photographs
President Donald Trump on Thursday struck landmark offers with Eli Lilly and Novo Nordisk that might mark a turning level in how many individuals can entry their expensive blockbuster weight problems medication.
Beneath the agreements, Medicare will begin protecting GLP-1s for weight problems for sure sufferers for the primary time starting in mid-2026 – a shift that can open entry to hundreds of thousands of older adults and will spur extra employers and different personal insurers to comply with go well with, some consultants mentioned. Novo Nordisk and Eli Lilly are additionally decreasing the costs that every one state Medicaid packages pays for GLP-1s, nevertheless it’s as much as states to choose into protection.
Weight problems drug protection amongst state Medicaid plans, employers and different personal insurers stays spotty as a result of $1,000 or extra month-to-month record costs of present GLP-1s, together with Eli Lilly’s weight problems injection Zepbound and Novo Nordisk’s competitor Wegovy.
The restricted insurance coverage protection has blocked out sufferers who cannot afford their hefty value tags. That lack of entry has led to mounting stress on well being plans and the federal government to increase protection — and the federal government agreements with drugmakers might mark a significant shift.
“I believe it’s going to begin with the federal government, begin with Medicare, and the insurers will shortly comply with,” Nick Fabrizio, an affiliate instructing professor in Cornell’s well being coverage program, informed CNBC. “I do assume that is coming.”
“It is a nice step in the direction of making an attempt to deal with a power and severe difficulty, and for these sufferers who could really feel like they don’t have any hope,” he mentioned.
Roughly 8 to 9 million individuals within the U.S. are utilizing GLP-1s, Eli Lilly CEO David Ricks mentioned at a briefing with reporters on Thursday. The added Medicare protection below the deal might usher in as many as 40 million new eligible sufferers, and immediate extra business plans to cowl the medicines, he mentioned.
The offers might additionally handle the lack of many sufferers with restricted or no insurance coverage protection for weight problems medication to entry them, by providing the therapies at a reduction on the Trump administration’s direct-to-consumer web site, TrumpRx.gov.
The month-to-month out-of-pocket price of present injections and upcoming drugs might vary from $50 to $350 beginning subsequent yr, relying on the dosage and insurance coverage protection a affected person has.
Nonetheless, there’s a legislation prohibiting Medicare from protecting weight reduction medication, so any adjustments must come from Congress. Eli Lilly’s Ricks informed reporters Thursday that for now, the federal government will launch an preliminary pilot program within the spring of 2026 below a brief authorized mechanism. It might be voluntary for Medicare prescription drug plans, so “it could be doable that just a few plans don’t take part, however I might count on virtually all do,” he mentioned.
However Ricks mentioned that it’s going to transition into a proper so-called Middle for Medicare and Medicaid Innovation pilot program in 2027, which suggests will probably be obligatory for all Medicare Half D plans.
“So we count on broad protection in all plans each in 2026 and past,” he mentioned.
Medicare protection could possibly be a sea change
Possible essentially the most notable function of the offers is Medicare protection of weight problems medication, as it would permit the therapies to achieve new sufferers in this system and will result in broader personal insurance coverage protection.
Beneath the offers, Eli Lilly and Novo Nordisk agreed to chop the value Medicare and Medicaid pay for GLP-1s to $245 per thirty days. In Medicare particularly, sure sufferers pays a copay of $50 per thirty days for all authorized makes use of of injectable and oral GLP-1 medication, together with diabetes and weight problems therapy.
However the Trump administration is placing some constraints on which Medicare beneficiaries will likely be eligible to obtain GLP-1s for weight problems and cardiovascular and metabolic advantages. Individuals who qualify embody sufferers with a physique mass index of 27 or above with prediabetes or established heart problems; individuals with a BMI of 30 or extra with associated well being circumstances; or these with extreme weight problems, or a BMI of 35 and above.
GLP-1s for weight reduction are authorized for a broader inhabitants: individuals who have weight problems or are chubby with one associated situation. In a word Thursday, Leerink Companions analyst David Risinger additionally mentioned it is unclear whether or not the federal government will permit sufferers to remain on a GLP-1 for weight problems after their BMI ranges drop.
Even with these restrictions, “I believe in follow, it is nonetheless going to cowl a good variety of individuals,” mentioned Darius Lakdawalla, chief scientific officer on the College of Southern California’s Schaeffer Middle.
JPMorgan analyst Chris Schott mentioned the eligibility standards imply 80% of the overweight inhabitants in Medicare might obtain protection for GLP-1s, regardless of the boundaries.
“Right this moment’s deal will open up significant entry to weight problems medication,” Schott mentioned in a word about Eli Lilly on Thursday.
Lakdawalla added that whereas there is not clear proof that non-public insurers will increase protection on the heels of presidency plans, “it is simply optically tougher for them to proceed to constrain protection when Medicare and Medicaid are protecting them.”
“That is going to exert some stress for business protection of those medication to increase as properly,” Lakdawalla mentioned.
Protection for GLP-1s for weight problems has ticked up barely, however stays sparse: A Might survey of greater than 300 corporations by the Worldwide Basis of Worker Profit Plans discovered that 36% supplied protection for GLP-1s for each weight reduction and diabetes, up from 34% in 2024.
Medicaid, direct-to-consumer choices might fill gaps
Lakdawalla mentioned the direct-to-consumer choices below the deal could possibly be helpful for people who find themselves underinsured, uninsured or could not have protection for weight problems medicines. Nonetheless, it is unclear what number of extra sufferers the medication will attain as a result of choices.
Each Eli Lilly and Novo Nordisk have launched decrease price choices for his or her medication for individuals paying in money and buying the medication straight via their web sites. However the offers with Trump will give these sufferers even larger reductions.
On TrumpRx, the typical month-to-month price for Wegovy, Zepbound and different injectable GLP-1s will begin at $350 and drop to $250 inside the subsequent two years, in keeping with senior Trump administration officers. Eli Lilly and Novo Nordisk each provided some GLP-1s on their direct-to-consumer platforms for as much as $450 to $500 per thirty days.
Beginning doses of weight problems drugs from Eli Lilly and Novo Nordisk — anticipated to hit the market subsequent yr — will likely be $149 per thirty days on TrumpRx, Medicare and Medicaid.
Eli Lilly on Thursday mentioned it will decrease costs by $50 by itself direct-to-consumer platform, LillyDirect, which already presents Zepbound and different medication at a reduction to cash-paying sufferers. The multidose pen of Zepbound will likely be accessible for $299 per thirty days on the lowest dose, with further doses being priced as much as $449 per thirty days.
When it comes to Medicaid, Cornell’s Fabrizio mentioned states will doubtless wish to begin protecting weight problems medication on the cheaper price level, “however the query is how will they pay for it?”
Round a dozen state Medicaid packages cowl weight problems medication, in keeping with 2024 estimates from KFF, a well being coverage analysis group. Whereas GLP-1s provide substantial well being advantages to Medicaid beneficiaries, state packages are already going through constrained budgets and administrative calls for.
Fabrizio added that elevating taxes to cowl the medication “could possibly be a sticky difficulty.”
Nonetheless, JPMorgan’s Schott mentioned providing decrease costs to Medicaid packages might result in a “vital improve in protection” in that channel, the place Zepbound has very restricted uptake.
[ad_2]
